Volume | 0 |
|
|||||
News | - |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Ariad Pharmaceuticals, Inc. | ARIA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
23.99 | 23.99 |
Trades | Shares Traded | Average Volume |
---|---|---|
0 | 0 | - |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 23.99 | USD |
Ariad Pharmaceuticals, Inc. Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 4.54B | - | - | - | 202.46 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Ariad News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARIA Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
Ariad Description
Ariad Pharmaceuticals is a biotechnology company with a focus on cancer drugs. The global oncology company aims to discover, develop, and commercialize small-molecule medicines to treat aggressive cancers where current therapies are inadequate, including leukemia. The vast majority of Ariad's revenue is derived from its product revenue segment, followed by its license collaboration and other revenue segments. The United States represents a majority of the company? oncology profits based on roughly half of its global sales. Ariad seeks market share outside the U.S. through industry partnerships. |